Pulmatrix (PULM) 10-Q 10 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 06, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-36199
Entity Registrant Name	PULMATRIX, INC.
Entity Central Index Key	0001574235
Entity Tax Identification Number	46-1821392
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	36 Crosby Drive
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Bedford
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01730
City Area Code	(781)
Local Phone Number	357-2333
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	PULM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		3,652,285

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 16,300	$ 19,173
Accounts receivable	570	928
Prepaid expenses and other current assets	712	742
Total current assets	17,582	20,843
Property and equipment, net	1,108	1,158
Operating lease right-of-use asset	10,094	10,309
Long-term restricted cash	1,472	1,472
Other long-term assets	135	176
Total assets	30,391	33,958
Current liabilities:
Accounts payable	721	1,915
Accrued expenses and other current liabilities	1,677	947
Operating lease liability	383	429
Deferred revenue	363	618
Total current liabilities	3,144	3,909
Deferred revenue, net of current portion		3,727
Operating lease liability, net of current portion	8,229	8,327
Total liabilities	11,373	15,963
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred Stock, $0.0001 par value — 500,000 shares authorized; 6,746 shares designated Series A convertible preferred stock; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value — 200,000,000 shares authorized; 3,652,285 shares issued and outstanding at March 31, 2024 and December 31, 2023
Additional paid-in capital	305,790	305,592
Accumulated deficit	(286,772)	(287,597)
Total stockholders’ equity	19,018	17,995
Total liabilities and stockholders’ equity	$ 30,391	$ 33,958

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	500,000	500,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	3,652,285	3,652,285
Common stock, shares outstanding	3,652,285	3,652,285
Series A Convertible Preferred Stock [Member]
Preferred stock, shares authorized	6,746	6,746
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 5,885	$ 1,499
Operating expenses:
Research and development	3,512	3,874
General and administrative	1,626	2,210
Total operating expenses	5,138	6,084
Income (loss) from operations	747	(4,585)
Other income (expense):
Interest income	160	222
Other expense, net	(82)	(85)
Total other income, net	78	137
Net income (loss)	$ 825	$ (4,448)
Net income (loss) per share attributable to common stockholders - basic	$ 0.23	$ (1.22)
Net income (loss) per share attributable to common stockholders - diluted	$ 0.23	$ (1.22)
Weighted average common shares outstanding - basic	3,652,285	3,650,769
Weighted average common shares outstanding - diluted	3,652,285	3,650,769

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022			$ 304,585	$ (273,476)	$ 31,109
Balance, shares at Dec. 31, 2022		3,639,185
Stock-based compensation			296		296
Net income (loss)				(4,448)	(4,448)
Issuance of common stock, net of issuance costs			53		53
Issuance of common stock, net of issuance costs, shares		13,100
Balance at Mar. 31, 2023			304,934	(277,924)	27,010
Balance, shares at Mar. 31, 2023		3,652,285
Balance at Dec. 31, 2023			305,592	(287,597)	17,995
Balance, shares at Dec. 31, 2023		3,652,285
Stock-based compensation			198		198
Net income (loss)				825	825
Balance at Mar. 31, 2024			$ 305,790	$ (286,772)	$ 19,018
Balance, shares at Mar. 31, 2024		3,652,285

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net income (loss)	$ 825	$ (4,448)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	59	32
Amortization of operating lease right-of-use asset	215	369
Stock-based compensation	198	296
Changes in operating assets and liabilities:
Accounts receivable	358	558
Prepaid expenses and other current assets	30	(86)
Other long-term assets	41	(510)
Accounts payable	(1,194)	(610)
Accrued expenses and other current liabilities	875	24
Operating lease liability	(144)	(422)
Deferred revenue	(3,982)	(131)
Net cash used in operating activities	(2,719)	(4,928)
Cash flows from investing activities:
Purchases of property and equipment	(154)
Net cash used in investing activities	(154)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs		53
Net cash provided by financing activities		53
Net decrease in cash, cash equivalents and restricted cash	(2,873)	(4,875)
Cash, cash equivalents and restricted cash — beginning of period	20,645	37,253
Total cash, cash equivalents and restricted cash	17,772	32,378
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	16,300	30,753
Restricted cash		153
Long-term restricted cash	1,472	1,472
Supplemental disclosures of non-cash investing and financing information:
Purchases of property and equipment not yet paid	244
Operating lease right-of-use asset obtained in exchange for operating lease obligation		$ 344

Organization

Organization	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Pulmatrix, Inc. (the “Company”) was incorporated in 2013 as a Delaware corporation. The Company is a clinical-stage biopharmaceutical company focused on the development of a novel class of inhaled therapeutic products. The Company’s proprietary dry powder delivery platform, iSPERSE ™ ™

Summary of Significant Accounti

Summary of Significant Accounting Policies and Recent Accounting Standards	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Recent Accounting Standards	2. Summary of Significant Accounting Policies and Recent Accounting Standards Basis of Presentation The condensed consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 28, 2024 (the “Annual Report”). The financial information as of March 31, 2024, and for the three months ended March 31, 2024 and 2023, is unaudited. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. The balance sheet data as of December 31, 2023 was derived from audited consolidated financial statements. The results of the Company’s operations for any interim periods are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year. Based on its current operating plan, the Company believes that its cash and cash equivalents as of March 31, 2024, will be adequate to fund its currently anticipated operating expenses for at least twelve months from the date these condensed consolidated financial statements are issued. The Company will need to secure additional funding in the future, from one or more equity or debt financings, collaborations, or other sources, in order to carry out all of the Company’s planned research and development activities and regulatory activities; commercialize product candidates; or conduct any substantial, additional development requirements requested by the FDA. Additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to secure additional capital, it will be required to significantly decrease the amount of planned expenditures and may be required to cease operations. In addition, any disruption in the capital markets could make any financing more challenging, and there can be no assurance that Pulmatrix will be able to obtain such financing on commercially reasonable terms or at all. Curtailment of operations would cause significant delays in the Company’s efforts to develop and introduce its products to market, which is critical to the realization of its business plan and the future operations of the Company. Use of Estimates In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. The most significant estimates and assumptions in the Company’s condensed consolidated financial statements include, but are not limited to, estimates of future expected costs in order to derive and recognize revenue and estimates related to clinical trial accruals and upfront deposits. Concentrations of Credit Risk Cash is a financial instrument that potentially subjects the Company to concentrations of credit risk. For all periods presented, substantially all of the Company’s cash was deposited in accounts at a single financial institution that management believes is creditworthy, and the Company has not incurred any losses to date. The Company is exposed to credit risk in the event of default by this financial institution for amounts in excess of the Federal Deposit Insurance Corporation insured limits. For the three months ended March 31, 2024, revenue from one customer accounted for 96 100 97 100 Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 2, Summary of Significant Accounting Policies and Recent Accounting Standards Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company did not adopt any new accounting pronouncements during the three months ended March 31, 2024 that had a material effect on its condensed consolidated financial statements. In December 2023, the FASB issued Accounting Standard Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures As of March 31, 2024, there are no other new, or existing recently issued, accounting pronouncements that are of significance, or potential significance, that impact the Company’s condensed consolidated financial statements.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2024
Prepaid Expenses And Other Current Assets
Prepaid Expenses and Other Current Assets	3. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: Schedule of Prepaid Expenses and Other Current Assets March 31, 2024 December 31, 2023 Clinical and consulting $ 184 $ 30 Insurance 134 232 Software and hosting costs 85 108 Other 309 372 Total prepaid expenses and other current assets $ 712 $ 742

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	4. Property and Equipment, Net Property and equipment, net consisted of the following: Schedule of Property and Equipment March 31, 2024 December 31, 2023 Laboratory equipment $ 1,811 $ 1,656 Leasehold improvements 454 - Office furniture and equipment 401 401 Computer equipment 237 237 Capital in progress - 600 Total property and equipment 2,903 2,894 Less accumulated depreciation and amortization (1,795 ) (1,736 ) Property and equipment, net $ 1,108 $ 1,158 Depreciation and amortization expense for the three months ended March 31, 2024 and 2023 was $ 59 32

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	5. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities March 31, 2024 December 31, 2023 Clinical and consulting $ 578 $ 347 Wages and incentives 558 70 Accrued purchases of property and equipment 244 389 Legal and patents 144 42 Other 153 99 Total accrued expenses and other current liabilities $ 1,677 $ 947

Significant Agreements

Significant Agreements	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Significant Agreements	6. Significant Agreements Development and Commercialization Agreement with Cipla Technologies LLC (“Cipla”) On April 15, 2019, the Company entered into a Development and Commercialization Agreement (the “Cipla Agreement”) with Cipla for the co-development and commercialization, on a worldwide exclusive basis, of PUR1900, the Company’s inhaled iSPERSE ™ The Company received a non-refundable upfront payment of $ 22.0 ™ Pursuant to the Second Amendment, the Company and Cipla were each responsible for 60% and 40%, respectively, of the Company’s overhead costs and the time spent by the Company’s employees and consultants on development of the Product (“Direct Costs”). The Company will share all other development costs with Cipla that are not Direct Costs, such as the cost of clinical research organizations, manufacturing costs and other third-party costs, on a 50/50 basis. Pursuant to the Third Amendment, the Company and Cipla agreed that, during the period commencing on January 6, 2024 and ending July 30, 2024 (the “Wind Down Period”), the Company will complete all Phase 2b activities, assign or license all patents to Cipla and their registration with the appropriate authorities in regions other than the United States, complete a physical and demonstrable technology transfer and secure all data from the Phase 2b study for inclusion in the safety database. The Company will share costs with Cipla during the Wind Down Period in the same proportions in effect with the Second Amendment discussed above, but subject to a maximum reimbursement amount by Cipla as approved by the joint steering committee. Accounting Treatment The Company concluded that because both it and Cipla are active participants in the arrangement and are exposed to the significant risks and rewards of the collaboration, the Company’s collaboration with Cipla is within the scope of Accounting Standards Codification (“ASC”) 808, Collaborative Arrangements Revenue from Contracts with Customers The Company initially determined the total transaction price to be $ 22.0 12.0 10.0 Revenue is recognized for the Cipla Agreement as the research and development services are provided using an input method, according to the ratio of costs incurred to the total costs expected to be incurred in the future to satisfy the Company’s obligations. In management’s judgment, this input method is the best measure of the transfer of control of the combined performance obligation. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company’s consolidated balance sheets, with amounts expected to be recognized in the next 12 months recorded as current. The Company concluded that the Third Amendment is a contract modification that should be accounted for as part of the existing contract. During the three months ended March 31, 2024 and 2023, the Company recognized $ 5.7 1.5 4.0 0.4

Common Stock

Common Stock	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Common Stock	7. Common Stock In May 2021, the Company entered into an At-The-Market Sales Agreement (the “Sales Agreement”) with H.C. Wainwright and Co., LLC (“HCW”) to act as the Company’s sales agent with respect to the issuance and sale of up to $ 20.0 75,000,000 20,000,000 75,000,000 Sales of common stock under the Sales Agreement are made pursuant to an effective shelf registration statement on Form S-3, which was filed with the SEC on May 26, 2021, and subsequently declared effective on June 9, 2021 (File No. 333-256502), and a related prospectus. HCW acts as the Company’s sales agent on a commercially reasonable efforts basis, consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of The Nasdaq Capital Market (“Nasdaq”). If expressly authorized by the Company, HCW may also sell the Company’s common stock in privately negotiated transactions. There is no specific date on which the ATM Offering will end, there are no minimum sale requirements and there are no arrangements to place any of the proceeds of the ATM Offering in an escrow, trust or similar account. HCW is entitled to compensation at a fixed commission rate of 3.0 During the three months ended March 31, 2024, no

Warrants

Warrants	3 Months Ended
	Mar. 31, 2024
Warrants
Warrants	8. Warrants There were no 7,791 38.31 105,778 29.53 Schedule of Warrants Outstanding Adjusted Number of Shares Issue Date Exercise Price Expiration Date Outstanding Exercisable December 17, 2021 $ 14.99 December 15, 2026 36,538 36,538 December 17, 2021 $ 13.99 December 17, 2026 281,047 281,047 February 16, 2021 $ 49.99 February 11, 2026 65,003 65,003 August 7, 2020 $ 35.99 July 14, 2025 90,743 90,743 August 7, 2020 $ 44.99 July 14, 2025 10,939 10,939 July 23, 2020 $ 35.99 July 14, 2025 77,502 77,502 July 13, 2020 $ 44.99 July 14, 2025 21,846 21,846 July 13, 2020 $ 35.99 July 14, 2025 334,800 334,800 April 8, 2019 $ 26.99 April 8, 2024 65,907 65,907 April 8, 2019 $ 33.74 April 3, 2024 39,871 39,871 February 12, 2019 $ 26.79 August 12, 2024 66,675 66,675 December 3, 2018 $ 77.99 June 3, 2024 46,876 46,876 June 15, 2015 $ 1,509.99 Five years after milestone achievement 15,955 - Total 1,153,702 1,137,747

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	9. Stock-based Compensation The Company sponsors the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan (the “Incentive Plan”). As of March 31, 2024, the Incentive Plan provided for the grant of up to 818,936 470,800 8 There were no options granted, exercised, forfeited or expired during the three months ended March 31, 2024. The following table summarizes stock options outstanding and exercisable as of March 31, 2024: Summary of Stock Option Activity Number of Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding — January 1, 2024 344,306 $ 20.92 7.54 $ - Outstanding — March 31, 2024 344,306 $ 20.92 7.29 $ - Exercisable — March 31, 2024 222,747 $ 28.64 6.72 $ - The Company records stock-based compensation expense related to stock options based on their grant-date fair value. As of March 31, 2024, there was $ 0.6 1.8 The following table presents total stock-based compensation expense for the three months ended March 31, 2024 and 2023: Schedule of Stock-based Compensation Expenses 2024 2023 Three Months Ended March 31, 2024 2023 Research and development $ 116 $ 72 General and administrative 82 224 Total stock-based compensation expense $ 198 $ 296

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Research and Development Activities The Company contracts with various other organizations to conduct research and development activities, including clinical trials. The scope of the services under contracts for research and development activities may be modified and the contracts, subject to certain conditions, may generally be cancelled by the Company upon written notice. In some instances, the contracts, subject to certain conditions, may be cancelled by the third party. As of March 31, 2024, the Company had no material noncancellable commitments not expected to be reimbursed under the Cipla Agreement. Legal Proceedings In the ordinary course of its business, the Company may be involved in various legal proceedings involving contractual and employment relationships, patent or other intellectual property rights, and a variety of other matters. The Company is not aware of any pending legal proceedings that would reasonably be expected to have a material impact on the Company’s financial position or results of operations.

Leases

Leases	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Leases	11. Leases Corporate Headquarters The Company has limited leasing activities as a lessee which are primarily related to its corporate headquarters, which were relocated during the third quarter of 2023. On January 7, 2022, the Company executed a lease agreement with Cobalt Propco 2020, LLC for its new corporate headquarters at 36 Crosby Drive, Bedford, Massachusetts. The leased premises comprise approximately 20,000 lease provides for base rent of $ 0.1 Other Leasing Activities The Company also leases small office equipment which is primarily short-term or immaterial in nature. Therefore, no right-of-use assets and lease liabilities are recognized for these leases. The components of lease expense for the Company for the three months ended March 31, 2024 and 2023 were as follows: Schedule of Components of Lease Expenses 2024 2023 Three Months Ended March 31, 2024 2023 Lease cost Fixed lease cost $ 407 $ 378 Variable lease cost 102 113 Total lease cost $ 509 $ 491 Other information Cash paid for amounts included in the measurement of lease liabilities $ 335 $ 431 Weighted-average remaining lease term — operating leases 9.7 0.4 Weighted-average discount rate — operating leases 11.00 % 8.40 % Maturities of lease liabilities due under these lease agreements as of March 31, 2024 are as follows: Schedule of Maturities of Lease Liabilities Operating Leases Maturity of lease liabilities 2024 (nine months) $ 969 2025 1,328 2026 1,366 2027 1,404 2028 1,444 2029 and thereafter 7,722 Total lease payments 14,233 Less: interest (5,621 ) Total lease liabilities $ 8,612 Reported as of March 31, 2024 Lease liabilities — short term $ 383 Lease liabilities — long term 8,229 Total lease liabilities $ 8,612

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes Although the Company had net income for the three months ended March 31, 2024, the Company had no no Management of the Company evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and determined that it is more likely than not that the Company will not recognize the benefits of the deferred tax assets. As a result, a full valuation allowance was recorded as of March 31, 2024 and December 31, 2023. The Company applies ASC 740, Income Taxes

Net Income (Loss) Per Share

Net Income (Loss) Per Share	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	13. Net Income (Loss) Per Share Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is calculated by dividing the weighted-average number common shares outstanding during the period, after taking into consideration any potentially dilutive effects from outstanding stock options or warrants. Basic and diluted net income (loss) per share were the same for the three months ended March 31, 2024 and 2023, as the effect of potentially dilutive securities would have been anti-dilutive. The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an anti-dilutive impact: Schedule of Computation of Anti-Dilutive Weighted-Average Shares Outstanding Three Months Ended March 31, 2024 2023 Options to purchase common stock 344,306 418,948 Warrants to purchase common stock 1,153,702 1,284,803 Total options and warrants to purchase common stock 1,498,008 1,703,751

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events The Company has completed an evaluation of all subsequent events after the balance sheet date of March 31, 2024 through the date the condensed consolidated financial statements were issued to ensure that the condensed consolidated financial statements include appropriate disclosure of events both recognized in the condensed consolidated financial statements as of March 31, 2024, and events which occurred subsequently but were not recognized in the condensed consolidated financial statements. The Company has concluded that no subsequent events have occurred that require disclosure, except as disclosed within the condensed consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Recent Accounting Standards (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 28, 2024 (the “Annual Report”). The financial information as of March 31, 2024, and for the three months ended March 31, 2024 and 2023, is unaudited. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. The balance sheet data as of December 31, 2023 was derived from audited consolidated financial statements. The results of the Company’s operations for any interim periods are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year. Based on its current operating plan, the Company believes that its cash and cash equivalents as of March 31, 2024, will be adequate to fund its currently anticipated operating expenses for at least twelve months from the date these condensed consolidated financial statements are issued. The Company will need to secure additional funding in the future, from one or more equity or debt financings, collaborations, or other sources, in order to carry out all of the Company’s planned research and development activities and regulatory activities; commercialize product candidates; or conduct any substantial, additional development requirements requested by the FDA. Additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to secure additional capital, it will be required to significantly decrease the amount of planned expenditures and may be required to cease operations. In addition, any disruption in the capital markets could make any financing more challenging, and there can be no assurance that Pulmatrix will be able to obtain such financing on commercially reasonable terms or at all. Curtailment of operations would cause significant delays in the Company’s efforts to develop and introduce its products to market, which is critical to the realization of its business plan and the future operations of the Company.
Use of Estimates	Use of Estimates In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. The most significant estimates and assumptions in the Company’s condensed consolidated financial statements include, but are not limited to, estimates of future expected costs in order to derive and recognize revenue and estimates related to clinical trial accruals and upfront deposits.
Concentrations of Credit Risk	Concentrations of Credit Risk Cash is a financial instrument that potentially subjects the Company to concentrations of credit risk. For all periods presented, substantially all of the Company’s cash was deposited in accounts at a single financial institution that management believes is creditworthy, and the Company has not incurred any losses to date. The Company is exposed to credit risk in the event of default by this financial institution for amounts in excess of the Federal Deposit Insurance Corporation insured limits. For the three months ended March 31, 2024, revenue from one customer accounted for 96 100 97 100
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 2, Summary of Significant Accounting Policies and Recent Accounting Standards
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company did not adopt any new accounting pronouncements during the three months ended March 31, 2024 that had a material effect on its condensed consolidated financial statements. In December 2023, the FASB issued Accounting Standard Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures As of March 31, 2024, there are no other new, or existing recently issued, accounting pronouncements that are of significance, or potential significance, that impact the Company’s condensed consolidated financial statements.

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Prepaid Expenses And Other Current Assets
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following: Schedule of Prepaid Expenses and Other Current Assets March 31, 2024 December 31, 2023 Clinical and consulting $ 184 $ 30 Insurance 134 232 Software and hosting costs 85 108 Other 309 372 Total prepaid expenses and other current assets $ 712 $ 742

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consisted of the following: Schedule of Property and Equipment March 31, 2024 December 31, 2023 Laboratory equipment $ 1,811 $ 1,656 Leasehold improvements 454 - Office furniture and equipment 401 401 Computer equipment 237 237 Capital in progress - 600 Total property and equipment 2,903 2,894 Less accumulated depreciation and amortization (1,795 ) (1,736 ) Property and equipment, net $ 1,108 $ 1,158

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities March 31, 2024 December 31, 2023 Clinical and consulting $ 578 $ 347 Wages and incentives 558 70 Accrued purchases of property and equipment 244 389 Legal and patents 144 42 Other 153 99 Total accrued expenses and other current liabilities $ 1,677 $ 947

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2024
Warrants
Schedule of Warrants Outstanding	Schedule of Warrants Outstanding Adjusted Number of Shares Issue Date Exercise Price Expiration Date Outstanding Exercisable December 17, 2021 $ 14.99 December 15, 2026 36,538 36,538 December 17, 2021 $ 13.99 December 17, 2026 281,047 281,047 February 16, 2021 $ 49.99 February 11, 2026 65,003 65,003 August 7, 2020 $ 35.99 July 14, 2025 90,743 90,743 August 7, 2020 $ 44.99 July 14, 2025 10,939 10,939 July 23, 2020 $ 35.99 July 14, 2025 77,502 77,502 July 13, 2020 $ 44.99 July 14, 2025 21,846 21,846 July 13, 2020 $ 35.99 July 14, 2025 334,800 334,800 April 8, 2019 $ 26.99 April 8, 2024 65,907 65,907 April 8, 2019 $ 33.74 April 3, 2024 39,871 39,871 February 12, 2019 $ 26.79 August 12, 2024 66,675 66,675 December 3, 2018 $ 77.99 June 3, 2024 46,876 46,876 June 15, 2015 $ 1,509.99 Five years after milestone achievement 15,955 - Total 1,153,702 1,137,747

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Summary of Stock Option Activity	There were no options granted, exercised, forfeited or expired during the three months ended March 31, 2024. The following table summarizes stock options outstanding and exercisable as of March 31, 2024: Summary of Stock Option Activity Number of Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding — January 1, 2024 344,306 $ 20.92 7.54 $ - Outstanding — March 31, 2024 344,306 $ 20.92 7.29 $ - Exercisable — March 31, 2024 222,747 $ 28.64 6.72 $ -
Schedule of Stock-based Compensation Expenses	The following table presents total stock-based compensation expense for the three months ended March 31, 2024 and 2023: Schedule of Stock-based Compensation Expenses 2024 2023 Three Months Ended March 31, 2024 2023 Research and development $ 116 $ 72 General and administrative 82 224 Total stock-based compensation expense $ 198 $ 296

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Schedule of Components of Lease Expenses	The components of lease expense for the Company for the three months ended March 31, 2024 and 2023 were as follows: Schedule of Components of Lease Expenses 2024 2023 Three Months Ended March 31, 2024 2023 Lease cost Fixed lease cost $ 407 $ 378 Variable lease cost 102 113 Total lease cost $ 509 $ 491 Other information Cash paid for amounts included in the measurement of lease liabilities $ 335 $ 431 Weighted-average remaining lease term — operating leases 9.7 0.4 Weighted-average discount rate — operating leases 11.00 % 8.40 %
Schedule of Maturities of Lease Liabilities	Maturities of lease liabilities due under these lease agreements as of March 31, 2024 are as follows: Schedule of Maturities of Lease Liabilities Operating Leases Maturity of lease liabilities 2024 (nine months) $ 969 2025 1,328 2026 1,366 2027 1,404 2028 1,444 2029 and thereafter 7,722 Total lease payments 14,233 Less: interest (5,621 ) Total lease liabilities $ 8,612 Reported as of March 31, 2024 Lease liabilities — short term $ 383 Lease liabilities — long term 8,229 Total lease liabilities $ 8,612

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Schedule of Computation of Anti-Dilutive Weighted-Average Shares Outstanding	The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an anti-dilutive impact: Schedule of Computation of Anti-Dilutive Weighted-Average Shares Outstanding Three Months Ended March 31, 2024 2023 Options to purchase common stock 344,306 418,948 Warrants to purchase common stock 1,153,702 1,284,803 Total options and warrants to purchase common stock 1,498,008 1,703,751

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Recent Accounting Standards (Details Narrative) - Customer Concentration Risk [Member]	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Revenue from Contract with Customer Benchmark [Member] | One Customer [Member]
Product Information [Line Items]
Concentration risk percentage	96%	100%
Accounts Receivable [Member] | One Customer [Member]
Product Information [Line Items]
Concentration risk percentage			100%
Accounts Receivable [Member] | Two Customer [Member]
Product Information [Line Items]
Concentration risk percentage	97%

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Prepaid Expenses And Other Current Assets
Clinical and consulting	$ 184	$ 30
Insurance	134	232
Software and hosting costs	85	108
Other	309	372
Total prepaid expenses and other current assets	$ 712	$ 742

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 2,903	$ 2,894
Less accumulated depreciation and amortization	(1,795)	(1,736)
Property and equipment, net	1,108	1,158
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	1,811	1,656
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	454
Office Furniture And Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	401	401
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	237	237
Capital In Progress [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 600

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation and amortization	$ 59	$ 32

Schedule of Accrued Expenses an

Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Clinical and consulting	$ 578	$ 347
Wages and incentives	558	70
Accrued purchases of property and equipment	244	389
Legal and patents	144	42
Other	153	99
Total accrued expenses and other current liabilities	$ 1,677	$ 947

Significant Agreements (Details

Significant Agreements (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Product Liability Contingency [Line Items]
Agreement description	Pursuant to the Second Amendment, the Company and Cipla were each responsible for 60% and 40%, respectively, of the Company’s overhead costs and the time spent by the Company’s employees and consultants on development of the Product (“Direct Costs”). The Company will share all other development costs with Cipla that are not Direct Costs, such as the cost of clinical research organizations, manufacturing costs and other third-party costs, on a 50/50 basis.
Transaction cost	$ 22,000
Revenue	5,885	$ 1,499
Cipla Agreement [Member] | Cipla Technologies LLC [Member]
Product Liability Contingency [Line Items]
Proceeds from related party debt	22,000
Revenue recognized	4,000
Deferred revenue	400
Cipla Agreement [Member] | Cipla Technologies LLC [Member] | Research and Development Service [Member]
Product Liability Contingency [Line Items]
Transaction cost	12,000
Revenue	5,700	$ 1,500
Cipla Agreement [Member] | Cipla Technologies LLC [Member] | Irrevocable License [Member]
Product Liability Contingency [Line Items]
Transaction cost	$ 10,000

Common Stock (Details Narrative

Common Stock (Details Narrative) - H.C.Wainwright and Co., LLC [Member] - Sale Agreement [Member] - USD ($)	1 Months Ended	3 Months Ended
	May 31, 2021	Mar. 31, 2024
Subsidiary, Sale of Stock [Line Items]
Sale of stock, consideration received on transaction	$ 20,000,000
Commission percentage	3%
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued in transaction		0
Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, consideration received on transaction	$ 75,000,000
Minimum [Member] | ATM Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, consideration received on transaction	$ 20,000,000

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details)	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Underlying Warrants, Outstanding Total	7,791
Warrant One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Dec. 17, 2021
Warrants, Exercise Price | $ / shares	$ 14.99
Warrants, Expiration Date	Dec. 15, 2026
Number of Shares Underlying Warrants, Outstanding Total	36,538
Number of Shares Underlying Warrants, Exercisable Total	36,538
Warrant Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Dec. 17, 2021
Warrants, Exercise Price | $ / shares	$ 13.99
Warrants, Expiration Date	Dec. 17, 2026
Number of Shares Underlying Warrants, Outstanding Total	281,047
Number of Shares Underlying Warrants, Exercisable Total	281,047
Warrant Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Feb. 16, 2021
Warrants, Exercise Price | $ / shares	$ 49.99
Warrants, Expiration Date	Feb. 11, 2026
Number of Shares Underlying Warrants, Outstanding Total	65,003
Number of Shares Underlying Warrants, Exercisable Total	65,003
Warrant Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Aug. 07, 2020
Warrants, Exercise Price | $ / shares	$ 35.99
Warrants, Expiration Date	Jul. 14, 2025
Number of Shares Underlying Warrants, Outstanding Total	90,743
Number of Shares Underlying Warrants, Exercisable Total	90,743
Warrant Five [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Aug. 07, 2020
Warrants, Exercise Price | $ / shares	$ 44.99
Warrants, Expiration Date	Jul. 14, 2025
Number of Shares Underlying Warrants, Outstanding Total	10,939
Number of Shares Underlying Warrants, Exercisable Total	10,939
Warrant Six [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Jul. 23, 2020
Warrants, Exercise Price | $ / shares	$ 35.99
Warrants, Expiration Date	Jul. 14, 2025
Number of Shares Underlying Warrants, Outstanding Total	77,502
Number of Shares Underlying Warrants, Exercisable Total	77,502
Warrant Seven [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Jul. 13, 2020
Warrants, Exercise Price | $ / shares	$ 44.99
Warrants, Expiration Date	Jul. 14, 2025
Number of Shares Underlying Warrants, Outstanding Total	21,846
Number of Shares Underlying Warrants, Exercisable Total	21,846
Warrant Eight [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Jul. 13, 2020
Warrants, Exercise Price | $ / shares	$ 35.99
Warrants, Expiration Date	Jul. 14, 2025
Number of Shares Underlying Warrants, Outstanding Total	334,800
Number of Shares Underlying Warrants, Exercisable Total	334,800
Warrant Nine [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Apr. 08, 2019
Warrants, Exercise Price | $ / shares	$ 26.99
Warrants, Expiration Date	Apr. 08, 2024
Number of Shares Underlying Warrants, Outstanding Total	65,907
Number of Shares Underlying Warrants, Exercisable Total	65,907
Warrant Ten [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Apr. 08, 2019
Warrants, Exercise Price | $ / shares	$ 33.74
Warrants, Expiration Date	Apr. 03, 2024
Number of Shares Underlying Warrants, Outstanding Total	39,871
Number of Shares Underlying Warrants, Exercisable Total	39,871
Warrant Twelve [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Feb. 12, 2019
Warrants, Expiration Date	Aug. 12, 2024
Number of Shares Underlying Warrants, Outstanding Total	66,675
Number of Shares Underlying Warrants, Exercisable Total	66,675
Warrant Eleven [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Exercise Price | $ / shares	$ 26.79
Warrant Fifteen [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Dec. 03, 2018
Warrants, Exercise Price | $ / shares	$ 77.99
Warrants, Expiration Date	Jun. 03, 2024
Number of Shares Underlying Warrants, Outstanding Total	46,876
Number of Shares Underlying Warrants, Exercisable Total	46,876
Warrant Eighteen [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Jun. 15, 2015
Warrants, Exercise Price | $ / shares	$ 1,509.99
Number of Shares Underlying Warrants, Outstanding Total	15,955
Number of Shares Underlying Warrants, Exercisable Total
Warrants, Expiration Date, Description	Five years after milestone achievement
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Underlying Warrants, Outstanding Total	1,153,702
Number of Shares Underlying Warrants, Exercisable Total	1,137,747

Warrants (Details Narrative)

Warrants (Details Narrative) - $ / shares	3 Months Ended
	Mar. 31, 2024	Apr. 01, 2024
Subsequent Event [Line Items]
Warrants issued or exercised	0
Purchase of warrants	7,791
Warrants exercise price	$ 38.31
Subsequent Event [Member]
Subsequent Event [Line Items]
Purchase of warrants		105,778
Warrants exercise price		$ 29.53

Summary of Stock Option Activit

Summary of Stock Option Activity (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Offsetting Assets [Line Items]
Weighted Average Exercise Price, Outstanding, Balance	$ 38.31
Equity Option [Member]
Offsetting Assets [Line Items]
Number of Options, Outstanding, Balance	344,306
Weighted Average Exercise Price, Outstanding, Balance	$ 20.92
Weighted Average Remaining Contractual Term (Years), Outstanding	7 years 3 months 14 days	7 years 6 months 14 days
Aggregate Intrinsic Value, Balance
Number of Options, Outstanding, Balance	344,306	344,306
Weighted Average Exercise Price, Outstanding, Balance	$ 20.92	$ 20.92
Aggregate Intrinsic Value, Balance
Number of Options, Exercisable	222,747
Weighted Average Exercise Price, Outstanding, Exercisable	$ 28.64
Weighted Average Remaining Contractual Term (Years), Exercisable	6 years 8 months 19 days
Aggregate Intrinsic Value, Exercisable

Schedule of Stock-based Compens

Schedule of Stock-based Compensation Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 198	$ 296
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	116	72
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 82	$ 224

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($) shares
Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation arrangement, number of shares authorized	818,936
Share based compensation arrangement, number of shares available for grant	470,800
Legacy Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation arrangement, award options outstanding number	8
Stock Award Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized stock-based compensation expenses | $	$ 0.6
Weighted-average period of unrecognized stock-based compensation expense	1 year 9 months 18 days

Schedule of Components of Lease

Schedule of Components of Lease Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Lease cost
Fixed lease cost	$ 407	$ 378
Variable lease cost	102	113
Total lease cost	509	491
Cash paid for amounts included in the measurement of lease liabilities	$ 335	$ 431
Weighted-average remaining lease term - operating leases	9 years 8 months 12 days	4 months 24 days
Weighted-average discount rate - operating leases	11%	8.40%

Schedule of Maturities of Lease

Schedule of Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Leases [Abstract]
2024 (nine months)	$ 969
2025	1,328
2026	1,366
2027	1,404
2028	1,444
2029 and thereafter	7,722
Total lease payments	14,233
Less: interest	(5,621)
Total lease liabilities	8,612
Lease liabilities — short term	383	$ 429
Lease liabilities — long term	$ 8,229	$ 8,327

Leases (Details Narrative)

Leases (Details Narrative) - Lease Agreement [Member] - Cobalt Propco [Member] $ in Millions		1 Months Ended
	Jan. 07, 2022 ft²	Mar. 31, 2024 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Area of land | ft²	20,000
Lessee, operating lease, description	lease provides for base rent of $0.1 million per month, payment of which began in March 2024, and which will increase 3% each year over the ten-year noncancellable term. The Company has the option to extend the lease for one additional five-year term and is responsible for real estate taxes, maintenance, and other operating expenses applicable to the leased premises.
Payments for rent | $		$ 0.1

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0

Schedule of Computation of Anti

Schedule of Computation of Anti-Dilutive Weighted-Average Shares Outstanding (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total options and warrants to purchase common stock	1,498,008	1,703,751
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total options and warrants to purchase common stock	344,306	418,948
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total options and warrants to purchase common stock	1,153,702	1,284,803